Alzheimer's Brain Edema, Bleeding Rates Reported in Lecanemab Real-World Study

Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share…

Alzheimer's Brain Edema, Bleeding Rates Reported in Lecanemab Real-World Study

(MedPage Today) -- Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well, a retrospective study at one specialty memory clinic showed. Infusion-related reactions occurred in...

Annovis Bio Launches Phase 3 Alzheimer's Trial, Expands Research Efforts

Annovis Bio Inc. has advanced its Alzheimer’s disease research by launching a comprehensive Phase 3 clinical trial targeting early-stage patients. The trial, which began in the first quarter of 2025, will enroll up to 760 participants to evaluate the effectiveness of buntanetap over an 18-month period. The pharmaceutical company is investigating buntanetap’s potential to address both symptomatic manifestations and underlying disease progression …

St. Louis/Missouri – Treatment with the anti-amyloid antibody lecanemab has proven safe for dementia patients in the first year and a half since its approval at a US clinic. According to the publication in JAMA Neurology (2025; DOI: 10.1001/jamaneurol.2025.1232), the dreaded side effects ARIA-A and ARIA-E are not occurring more frequently...

A study by the Washington University School of Medicine of Sant Louis, in the United States, published this month at JAMA Neurology, evaluated the safety of lecanemab (Leqembi in its form of commercialization by Esai and Biogen) in a real clinical environment against alzhéimer in its early stages of evolution. 234 patients with mild or very mild alzhéimer who received Lecanemab infusions were studied. The study found that 1 percent of patients e…

A new drug, lecanemab, has shown promising results in the fight against Alzheimer's in recent clinical trials. The drug, a monoclonal antibody, targets beta-amyloid plaques, a protein that accumulates in the brains of people with Alzheimer's and is believed to contribute to cognitive decline. Results of the Phase 3 Clarity AD trial, published in the New England Journal of Medicine, showed that lecanemab significantly slowed cognitive decline by …